Skip to content
naulon
Not checkedNot checked for notices yet.

Pretomanid development and its clinical roles in treating tuberculosis

Ginenus Fekadu, Tadesse Tolossa, Ebisa Turi and 2 more

Journal of Global Antimicrobial Resistance · 2022

doi:10.1016/j.jgar.2022.09.001 (opens in a new tab)

We email you when a new notice or a question about this paper appears.

Abstract

ABSTRACT: Tuberculosis (TB) is the leading infectious cause of mortality worldwide. Despite the development of different antituberculosis drugs, managing resistant mycobacteria is still challenging. The discovery of novel drugs and new methods of targeted drug delivery have the potential to improve treatment outcomes, lower the duration of treatment, and reduce adverse events. Following bedaquiline and delamanid, pretomanid is the third medicine approved as part of a novel drug regimen for treating drug-resistant TB. It is a promising drug that has the capacity to shape TB treatment and achieve the End TB strategy set by the World Health Organization. The effectiveness of pretomanid has been reported in different observational and clinical studies. However, long-term safety data in humans are not yet available and the pretomanid-based regimen is recommended under an operational research framework that prohibits its wider and programmatic use. Further research is needed before pretomanid can be celebrated as a promising candidate for the treatment of different categories of TB and specific patients. This review covers the update on pretomanid development and its clinical roles in treating Mycobacterium tuberculosis.

Abstract licence: CC BY-NC-ND

References63

  1. 28.
  2. 33.
  3. 34.
  4. 35.
  5. 40.

35 more references, whose wording the paper’s licence keeps private.

All 63 references

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.